



## Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024

January 23, 2024

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 23, 2024-- [Exelixis, Inc.](#) (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2023 financial results will be released on Tuesday, February 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website.

To access the conference call, please register using this [link](#). Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto [www.exelixis.com](#) and proceed to the Event Calendar page under the Investors & News heading. A webcast replay of the conference call will also be archived on [www.exelixis.com](#) for one year.

### About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit [www.exelixis.com](#), follow [@ExelixisInc](#) on X (Twitter), like [Exelixis, Inc.](#) on Facebook and follow [Exelixis](#) on LinkedIn.

*Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.*

View source version on [businesswire.com](#): <https://www.businesswire.com/news/home/20240123144117/en/>

### Investors Contact:

Varant Shirvanian  
Associate Director, Investor Relations  
Exelixis, Inc.  
650-837-8194  
[vshirvanian@exelixis.com](mailto:vshirvanian@exelixis.com)

### Media Contact:

Hal Mackins  
For Exelixis, Inc.  
415-994-0040  
[hal@torchcommunications.com](mailto:hal@torchcommunications.com)

Source: Exelixis, Inc.